Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD

Recruiting now

Conditions studied: Wet Age-related Macular Degeneration (wAMD)

In brief

This study is designed to evaluate long-term safety and efficacy of AL-001 ophthalmic injection following suprachoroidal space(SCS) administration in subjects with wAMD. Eligible patients, are those who were previously enrolled in a clinical study in which they received a single dose of AL-001 administered via suprachoroidal space injection.

Key facts

Study ID

NCT06718816

Run by

Beijing Anlong Biopharmaceutical Co., Ltd.

People needed

21

Starts

2024-12-09

Expected to finish

2029-06-30

Last updated by the study team

2024-12-05

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subjects enrolled in AL-001 study and received AL-001 ophthalmic injection.
• The subject or their legal representative agrees to participate in this study and signs a written ICF.
• The subjects are willing and able to follow planned visits and procedures.

You may not qualify if…

• None

Where it is running

• Chinese Academy of Medical Sciences & Peking Union Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.